Isofol Medical

Isofol is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate, Modufolin®, is predicted to improve the outlook for cancer patients undergoing chemotherapy treatment with a range of antimetabolites. Isofol’s ongoing clinical trials are focusing on colorectal cancer and osteosarcoma. Isofol collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates.

Full Story >

stor orange

Modufolin® development

Modufolin® is a folate-based bio-modulator designed to replace leucovorin/levoleucovorin as the preferred treatment to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-flluorouracil). It is currently being evaluated in three Phase I/II studies, two in colorectal cancer and one in osteosarcoma.
 
Although several modern chemo drugs have been introduced that dramatically improve the treatment of many cancer diseases, they show limited effect in treating solid tumors. 5-FU and leucovorin/levoleucovorin is still the core treatment used today for colorectal cancer and Modufolin® has the potential to enable 5-FU to work more effectively.

Read more about Modufolin

Stay informed

Click the link below to stay informed about our progress.

Clinical trials

To find out the latest news about our ongoing clinical phase II trial please go to:

Development pipeline

Click the link below to find out more about our development pipeline:

News & Press information

Stockholm Corporate Finance Life Science Day 2015
3/4/2015: Isofol’s Chief Scientific Officer, Anders Vedin presented at the Stockholm Corporate Finance Life Science Day 2015 at Operaterrassen in Stockholm.
Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset
2/4/2015: Gothenburg, Sweden, Cambridge UK, and Clinton NJ – February 2015 – Isofol (www.isofolmedical.com), a clinical stage pharmaceutical company based in Gothenburg, Sweden, announces that following an internal review, it has launched a global program to identify one or more strategic partners for commercialization of its Modufolin® chemotherapy asset. The Sage Group (based in Europe, USA and Asia) has been appointed by Isofol to assist the company in this endeavor. The overall objective is to identify a well-­‐established pharma partner who will work with the company to exploit the value of Modufolin® in what is believed to be a multi billion dollar market.
Isofol Medical AB, Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden
Phone: +46 (0) 707 64 65 00 E-mail: info@isofolmedical.com